484 related articles for article (PubMed ID: 23376607)
1. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
[TBL] [Abstract][Full Text] [Related]
2. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
[TBL] [Abstract][Full Text] [Related]
3. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
[TBL] [Abstract][Full Text] [Related]
4. A three-centre experience with adalimumab for the treatment of non-infectious uveitis.
Dobner BC; Max R; Becker MD; Heinz C; Veltrup I; Heiligenhaus A; Barisani-Asenbauer T; Mackensen F
Br J Ophthalmol; 2013 Feb; 97(2):134-8. PubMed ID: 23212204
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
6. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study.
Sen ES; Sharma S; Hinchcliffe A; Dick AD; Ramanan AV
Rheumatology (Oxford); 2012 Dec; 51(12):2199-203. PubMed ID: 22923752
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab therapy for refractory uveitis: a pilot study.
Diaz-Llopis M; García-Delpech S; Salom D; Udaondo P; Hernández-Garfella M; Bosch-Morell F; Quijada A; Romero FJ
J Ocul Pharmacol Ther; 2008 Jun; 24(3):351-61. PubMed ID: 18476805
[TBL] [Abstract][Full Text] [Related]
8. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.
Gül A; Tugal-Tutkun I; Dinarello CA; Reznikov L; Esen BA; Mirza A; Scannon P; Solinger A
Ann Rheum Dis; 2012 Apr; 71(4):563-6. PubMed ID: 22084392
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.
Schaap-Fogler M; Amer R; Friling R; Priel E; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):633-40. PubMed ID: 24366669
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal adalimumab for refractory uveitis-related macular edema.
Androudi S; Tsironi E; Kalogeropoulos C; Theodoridou A; Brazitikos P
Ophthalmology; 2010 Aug; 117(8):1612-6. PubMed ID: 20378179
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
Bawazeer A; Raffa LH; Nizamuddin SH
Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis.
Farvardin M; Afarid M; Mehryar M; Hosseini H
Retina; 2010 Oct; 30(9):1530-5. PubMed ID: 20924267
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for refractory uveitis-related macular edema.
Acharya NR; Hong KC; Lee SM
Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.
Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL
Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]